From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history

Rintatolimod (tradename Ampligen®) is a mismatched, double-stranded RNA molecule with immunomodulatory and antiviral properties. The drug acts as a TLR3 agonist which stimulates the production of interferons and tumor necrosis factors. It is manufactured by AIM ImmunoTech, formerly known as Hemispherx Biopharma.[1]

It has been shown to raise natural killer cell (NK) function.[2] Numerous studies have found evidence of reduced NK function in patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).[3][4][5][6][7]

As of 2016, it has been approved for severe ME/CFS in Argentina.[8][9] That same year it was approved for an Early Access Program in EU and Turkey.[10] The US Food and Drug Administration (FDA) have not approved Ampligen for wide use in ME/CFS.[11] On January 2, 2018, the FDA approved the compassionate care (expanded access) program AMP-511 which "will allow treatment of up to 100 ME/CFS patients at any one time at approved clinical infusion therapy sites."[12]

History[edit | edit source]

Ampligen® was based on a double-stranded RNA (dsRNA) compound developed by the pharmaceutical company, Merck, in the 1960s, as a potential cancer drug. Though effective in the petri dish, the original compound proved to be too toxic for human use.[13][14]

William A. Carter, MD, a researcher at Johns Hopkins University, was able to modify the compound in the 1970s to reduce its toxicity (see section below on "Mechanism of action"). The new compound was named Ampligen®, short for “AMPLIfied GENetic activity.” In the 1980s, while a researcher at Hahnemann University in Philadelphia, Dr. Carter obtained the license for the compound from Johns Hopkins University. He and several other researchers at Hahnemann University affiliated with a small company, Hemispherx, now called AIM ImmunoTech, to manufacture it.[13]

In the late 1980s, AIM ImmunoTech partnered with Dupont to start clinical trials for Ampligen®. After a couple years, Dupont severed its business relationship with AIM ImmunoTech.[15]

Through the years, Dr. Carter's confidence in Ampligen®'s ability to stimulate the body's immune system lead to him offering the drug as a treatment for a variety of diseases including cancer, AIDS, chronic fatigue syndrome, hepatitis C, Gulf War Illness, swine flu, and ebola.[16][17] AIM ImmunoTech stated: "...we believe that Ampligen® may have broad-spectrum anti-viral and anti-cancer properties."[18]

This over-confidence resulted in a class action suit by stockholders in 2013.[13]

Testing for efficacy in ME/CFS started in 1990 and continues to the present (see section below on "Drug approval status"). Testing for other conditions has been sporadic. In 2016, the University of Pittsburgh was sponsoring Phase I/II studies using Ampligen® as an adjunct treatment in ovarian, peritoneal, and colorectal cancer.[19][20] Hahnemann University and AIM ImmunoTech are collaborating on Phase II studies for Ampligen® as a single agent for renal cell carcinoma and melanoma. Georgia Regents University is in the preclinical stage of testing Ampligen® as part of a combination therapy for colorectal cancer and melanoma.[21]

In late fall 2015, Dr. Francis Collins announced that the National Institutes of Health (NIH) was considering the possibility of sponsoring a clinical trial for Ampligen®, as well as Rituximab and other treatments.[22] By the end of 2016, the NIH has not announced any further plans for a clinical trial for either drug.

At the 12th International IACFS/ME Research and Clinical Conference in October 2016, representatives from AIM ImmunoTech announced "that a retrospective analysis of the AMP-516 Phase III trial of Ampligen® in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME), segmented primarily by disease duration, showed that 51% of Ampligen® treated patients in a cohort with a disease duration of two to eight years vs. 18% of placebo patients demonstrated at least 25% improvement in placebo-adjusted exercise tolerance whereas the patient subset with less than two years or greater than eight years of disease duration failed to show a clinically-significant response."[23]

Marketing history[edit | edit source]

Mechanism of action[edit | edit source]

Poly I:C12U Source: Hemispherx Biopharma, Inc

The chemical formation of Ampligen® begins with the known immunostimulant called Polyinosinic:polycytidylic acid (usually abbreviated Poly I:C). Poly I:C is a mismatched double-stranded RNA (dsRNA) with one strand being a polymer of inosinic acid and the other strand a polymer of cytidylic acid.[24]

Poly I:C is structurally similar to the type of dsRNA present in some viruses. When introduced into the body it stimulants the immune system because the body thinks a virus is present.

Ampligen® is formed when uridine (one of the five standard nucleosides which form the building blocks of RNA) is introduced into this Poly I:C strand, altering the strand to Poly I:C12U.[24]

As a result, one strand of the dsRNA is a homopolymer, poly rI and annealed to this strand is a heteropolymer, polyC12U.[24]

This alteration increases the compound's instability and shortens the half life to less than 40 minutes after IV administration. Plasma RNase (an enzyme naturally present in blood) degrades the Ampligen® compound into separate ribonucleotides which are completely natural degradation products the body can easily handle, thus lessening its toxicity.[24]

Ampligen® is a TLR3 agonist.[24] It stimulates the production of toll-like receptor 3 (TLR3), which is a naturally occurring protein. we TLR3 recognizes the dsRNA present in some viruses, such as retroviruses, and stimulates a series of biochemical reactions that result is an increase in the production of interferon. Interferon, an important player in the body's immune system, protects against viral infections and activates immune cells, such as NKC.

Evidence[edit | edit source]

Coxsackie B[edit | edit source]

In a mouse model, Ampligen® was found to be protective of Coxsackie B3-induced myocarditis.[25]

HHV6[edit | edit source]

  • 1994, A study done by the Department of Biochemistry, Temple University School of Medicine, Philadelphia, using IV therapy of Ampligen® "resulted in a significant decrease in Human herpesvirus 6 activity (P < .01) and in downregulation of the 2-5A synthetase/RNase L pathway in temporal association with clinical and neuropsychological improvement."[26]

Efficacy in ME/CFS[edit | edit source]

  • 1995, Long Term Improvements in Patients with Chronic Fatigue Syndrome Treated with Ampligen®[27]
  • 2001, Chronic Fatigue Syndrome, Ampligen, and Quality of Life: A Phenomenological Perspective[28]
  • 2004, A study done at the Rega Institute for Medical Research, Belgium on coxsackie B3 virus-induced myocarditis in C3H/HeNHsd mice show Ampligen® markedly reduced the virus titers in the normalized heart electrocardiographic parameters[25]
  • 2012, A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome[29]
The increase of baseline in mean exercise tolerance tests (ETT) improved 95.7% in the group on Ampligen® and 28.2% in the placebo group. (p value= 0.047; slide 81)[30]
A greater percentage of Ampligen® patients (68.0%) decreased their use of concomitant medications used in an attempt to palliate symptoms of CFS compared to the placebo group (54.6%). (slide 59)[30]
No Evidence for induction of autoantibodies with Ampligen® by assessment of Anti-dsDNA and Rheumatoid Factor in 64 randomly selected patients in controlled study AMP-516 at week 32; In the placebo group, 0% developed Anti-dsDNAand one patient (3.7%) developed Rheumatoid Factor autoantibodies. (slide 54)
  • 2015, Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME): Characteristics of Responders to Rintatolimod[31]
See Ampligen Exercise Tolerance - graph 1 | last4
  • 2015, David Strayer, et al., published "Low NK Cell Activity in Chronic Fatigue Syndrome (CFS) and Relationship to Symptom Severity," in the Journal of Clinical & Cellular Immunology. The study reviewed previous studies that concluded that the more decreased the Natural Killer cell cytotoxicity was in patients, the greater the CFS severity. The study, also, reported that in vitro exposure of peripheral blood mononuclear cells from CFS patients (fulfilling both the CDC 1988 and 1994 case definitions) to Ampligen® increased Natural Killer cell cytotoxicity 100-178%.[2]
  • 2016, William M. Mitchell published a review in the journal, Expert Review of Clinical Pharmacology that stated: "Rintatolimod has achieved statistically significant improvements in primary endpoints in Phase II and Phase III double-blind, randomized, placebo-controlled clinical trials with a generally well tolerated safety profile and supported by open-label trials in the United States and Europe." Mitchell is the Chairman of the Board for AIM ImmunoTech and a Professor of Pathology, Microbiology and Immunology at Vanderbilt University School of Medicine, Nashville, Tennessee.[32]

Drug approval status[edit | edit source]

United States[edit | edit source]

Source: Hemispherx Biopharma, Inc, Dec 2012

Ampligen® has been passed through five different FDA review divisions since 1990. Hemispherx Biopharma, Inc, now AIM ImmunoTech, wrote in a presentation to the FDA on Dec 20, 2012: "Most products have [the] same review Division during their entire development. Guidance from five (5) different Divisions [has provided] diverged/conflicting advice on major points, such as: interpreting primary endpoints (method of analysis), its collection and analysis, and different thresholds for determining toxicity and safety. In contrast, AIM ImmunoTech has had the same medical monitor for more than 20 years (Dr. David Strayer)."[24]

Source: FDA website
History of AIM ImmunoTech’s application to the FDA for Ampligen[33]

Expanded access[edit | edit source]

The AMP-511 expanded access program allows a limited number of patients access to Ampligen.

Europe[edit | edit source]

In 2016 Ampligen® started being made available on a limited basis in Europe.[34]

South America[edit | edit source]

Argentina (Argentine Republic) has approved the use of Ampligen® for severe ME/CFS on August 23, 2016. [35] Approval is limited to ME/CFS patients who are severely disabled and who have been diagnosed for more than one year.[21]

Notable studies[edit | edit source]

Clinics[edit | edit source]

The two clinics that are approved to deliver Ampligen infusions are Sierra Internal Medicine in Incline Village, Nevada, and Hunter-Hopkins Center, North Carolina. Patient numbers are limited. Some patients have moved near to a clinic to minimise travel for the frequent infusions.[40]

Experiences of patients on Ampligen®[edit | edit source]

Talks, interviewsand news articles[edit | edit source]

Learn more[edit | edit source]

See also[edit | edit source]

References[edit | edit source]

  1. AIM ImmunoTech. "Products". AIM ImmunoTech Inc. Retrieved November 20, 2019.
  2. 2.0 2.1 Scott, Victoria; Strayer, David (2015). "Low NK Cell Activity in Chronic Fatigue Syndrome (CFS) and Relationship to Symptom Severity". Journal of Clinical & Cellular Immunology. 06 (04). doi:10.4172/2155-9899.1000348. ISSN 2155-9899.
  3. Barker, Edward; Fujimura, Sue F.; Fadem, Mitchell B.; Landay, Alan L.; Levy, Jay A. (January 1, 1994). "Immunologic Abnormalities Associated with Chronic Fatigue Syndrome". Clinical Infectious Diseases. 18 (Supplement_1): S136–S141. doi:10.1093/clinids/18.Supplement_1.S136. ISSN 1537-6591.
  4. Whiteside, Theresa L; Friberg, Diana (September 1998). "Natural killer cells and natural killer cell activity in chronic fatigue syndrome". The American Journal of Medicine. 105 (3): 27S–34S. doi:10.1016/S0002-9343(98)00155-7.
  5. Brenu, Ekua Weba; Huth, Teilah K.; Hardcastle, Sharni L.; Fuller, Kirsty; Kaur, Manprit; Johnston, Samantha; Ramos, Sandra B.; Staines, Don R.; Marshall-Gradisnik, Sonya M. (April 2014). "Role of adaptive and innate immune cells in chronic fatigue syndrome/myalgic encephalomyelitis". International Immunology. 26 (4): 233–242. doi:10.1093/intimm/dxt068. ISSN 1460-2377.
  6. Fletcher, Mary Ann; Maher, Kevin J; Klimas, Nancy (April 2002), "Natural killer cell function in chronic fatigue syndrome", Clinical and Applied Immunology Reviews, 2 (2): 129–139, doi:10.1016/S1529-1049(01)00047-2
  7. Brenu, Ekua W; van Driel, Mieke L; Staines, Donald R; Ashton, Kevin J; Hardcastle, Sharni L; Keane, James; Tajouri, Lotti; Peterson, Daniel; Ramos, Sandra B; Marshall-Gradisnik, Sonya M (2012), "Longitudinal investigation of natural killer cells and cytokines in chronic fatigue syndrome/myalgic encephalomyelitis", Journal of Translational Medicine, 10: 88, doi:10.1186/1479-5876-10-88
  8. Hemispherx Biopharma, Inc. (August 23, 2016). "Hemispherx Biopharma Announces Major Breakthrough: Approval for Commercial Sale of Rintatolimod (U.S. Tradename: Ampligen®) to Treat Severe Cases of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) in the Argentine Republic". GlobeNewswire News Room. Retrieved August 13, 2018.
  9. "Hemispherx Biopharma, Inc. Executive Informational Overview" (PDF). Crystal Research Associates. November 27, 2016.
  10. George, John (July 25, 2016). "Hemispherx ships Ampligen for European chronic fatigue syndrome program". Retrieved August 13, 2018.
  11. 11.0 11.1 11.2 "Experimental treatments". American Myalgic Encephalomyelitis and Chronic Fatigue Syndrome Society. Retrieved March 18, 2021.
  12. "Hemispherx Biopharma Inc. Announces Advancement in Expanded Access Program for Ampligen in the Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome". GlobeNewswire. January 2, 2019. Retrieved February 10, 2019.
  13. 13.0 13.1 13.2 "FRATER VS HEMISPHERX BIOPHARMA, Case 2:12-cv-07152-WY" (PDF). Pomerantz Law Firm. May 20, 2013. Retrieved September 26, 2019.
  14. "Ampligen I: Effectiveness". Phoenix Rising. Retrieved September 26, 2019.
  15. "Twisted History: Ampligen and CFS". Phoenix Rising. Retrieved September 26, 2019.
  16. "Hemispherx Presents Evidence of Ampligen Synergies with Existing,Antivirals at International Avian Influenza Conference ( PARIS--(BUSINESS WIRE)--Jun 4 2007 - H...)". Retrieved September 26, 2019.
  17. Britt, Russ. "Tiny biotech says it may have an answer for Ebola". MarketWatch. Retrieved February 4, 2020.
  18. ImmunoTech, A. I.M. "Home". AIM ImmunoTech Inc. Retrieved September 26, 2019.
  19. ImmunoTech, A. I.M. "Pipeline". AIM ImmunoTech Inc. Retrieved February 4, 2020.
  20. ImmunoTech, A. I.M. (August 15, 2019). "Hemispherx Issues 2019 Second Quarter Report Citing Strong Steady Progress in Cancer Clinical Trials". AIM ImmunoTech Inc. Retrieved November 20, 2019.
  21. 21.0 21.1 21.2 Crystal Research Associates (November 27, 2016), Hemispherx Biopharma, Inc. (PDF) (Executive Informational Overview)
  22. "NIH considering Ampligen and Rituximab trials". #MEAction. December 21, 2015. Retrieved September 26, 2019.
  23. Inc, Hemispherx Biopharma (October 31, 2016). "Hemispherx Biopharma Announces Identification of High Responder Patient Subgroup from Ampligen® Phase III Trial in Patients with CFS/ME". GlobeNewswire News Room. Retrieved September 26, 2019.
  24. 24.0 24.1 24.2 24.3 24.4 24.5 24.6 Hemispherx Biopharma, Inc. (December 20, 2012). "Ampligen® for the Treatment of Chronic Fatigue Syndrome" (PDF).
  25. 25.0 25.1 Padalko, Elizaveta; Nuyens, Dieter; De Palma, Armando; Verbeken, Erik; Aerts, Joeri L.; De Clercq, Erik; Carmeliet, Pete; Neyts1, Johan (2004), "The Interferon Inducer Ampligen [Poly(I)-Poly(C12U)] Markedly Protects Mice against Coxsackie B3 Virus-Induced Myocarditis", Antimicrobial Agents and Chemotherapy, 48 (1): 267–274, doi:10.1128/AAC.48.1.267-274.2004, PMID 14693549
  26. Suhadolnik, RJ; Reichenbach, NL; Hitzges, P; Sobol, RW; Peterson, DL; Henry, B; Ablashi, DV; Müller, WE; Schröder, HC; Carter, WA (January 1994), "Upregulation of the 2-5A synthetase/RNase L antiviral pathway associated with chronic fatigue syndrome.", Clinical Infectious Disease, 18 (Suppl 1): S96-104, PMID 8148461
  27. 27.0 27.1 Strayer, DR; Carter, W; Strauss, KI; Brodsky, I; Suhadolnik, R; Ablashi, D; Henry, B; Mitchell, WM; Bastien, S; Peterson, D (1995). "Long Term Improvements in Patients with Chronic Fatigue Syndrome Treated with Ampligen". Journal of Chronic Fatigue Syndrome. 1 (1): 35–53.
  28. Snell, Christopher R.; Stevens, Staci R.; Vanness, J. Mark (January 2001). "Chronic Fatigue Syndrome, Ampligen, and Quality of Life: A Phenomenological Perspective". Journal of Chronic Fatigue Syndrome. 8 (3–4): 117–121. doi:10.1300/J092v08n03_11. ISSN 1057-3321.
  29. 29.0 29.1 Strayer, DR; Carter, WA; Stouch, BC; Stevens, SR; Bateman, L; Cimoch, PJ; Lapp, CW; Peterson, DL; Chronic Fatigue Syndrome AMP-516 Study Group; Mitchell, WM (2012), "A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome.", PLoS One, 7 (3): e31334, doi:10.1371/journal.pone.0031334, PMID 22431963
  30. 30.0 30.1 Strayer, David R.; Carter, William A.; Stouch, Bruce C.; Stevens, Staci R.; Bateman, Lucinda; Cimoch, Paul J.; Lapp, Charles W.; Peterson, Daniel L.; Chronic Fatigue Syndrome AMP-516 Study Group (2012). "A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome". PloS One. 7 (3): e31334. doi:10.1371/journal.pone.0031334. ISSN 1932-6203. PMC 3303772. PMID 22431963.
  31. Strayer, David R; Stouch, Bruce C; Stevens, Staci R.; Bateman, Lucinda; Lapp, Charles W; Peterson, Daniel L; Carter, William A; Mitchell, William M (August 8, 2015), "Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME): Characteristics of Responders to Rintatolimod" (PDF), Journal of Drug Research and Development, 1 (1), doi:10.16966/2470-1009.103
  32. 32.0 32.1 Mitchell, William M (June 2, 2016). "Efficacy of rintatolimod in the treatment of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME)". Expert Review of Clinical Pharmacology. 9 (6): 755–770. doi:10.1586/17512433.2016.1172960. ISSN 1751-2433. PMC 4917909. PMID 27045557.
  33. "Drug Development for Myalgic Encephalomyelitis and Chronic Fatigue Syndrome (ME and CFS): Questions and Answers". FDA. February 5, 2013. Archived from the original on February 8, 2013. Retrieved February 5, 2013.
  34. George, John (July 25, 2016). "Hemispherx ships Ampligen for European chronic fatigue syndrome program". Philadelphia Business Journal. Retrieved September 26, 2019.
  35. Hemispherx Biopharma Announces Major Breakthrough: Approval for Commercial Sale of Rintatolimod (U.S. Tradename: Ampligen®) to Treat Severe Cases of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) in the Argentine Republic - NasDaq GlobeNewswire
  36. Ablashi, DV; Berneman, ZN; Williams, M; Strayer, D; Kramarsky, B; Suhadolnik, RJ; Reichenbach, N; Hiltzges, P; Komaroff, AL (1994), "Ampligen inhibits human herpesvirus-6 in vitro", In Vivo, 8 (4): 587-91, PMID 7893986
  37. Strayer, DR; Carter, WA; Brodsky, I; Cheney, P; Peterson, D; Salvato, P; Thompson, C; Loveless, M; Shapiro, DE; Elsasser, W (1994). "A controlled clinical trial with a specifically configured RNA drug, poly(I).poly(C12U), in chronic fatigue syndrome". Clinical Infectious Diseases. 18 (Suppl 1): S88-95. PMID 8148460.
  38. Padalko, E.; Nuyens, D.; De Palma, A.; Verbeken, E.; Aerts, J.L.; De Clercq, E.; Carmeliet, P.; Neyts, J. (January 1, 2004). "The Interferon Inducer Ampligen [Poly(I)-Poly(C12U)] Markedly Protects Mice against Coxsackie B3 Virus-Induced Myocarditis". Antimicrobial Agents and Chemotherapy. 48 (1): 267–274. doi:10.1128/AAC.48.1.267-274.2004. ISSN 0066-4804. PMC 310159. PMID 14693549.
  39. Strayer, David R.; Young, Diane; Mitchell, William M. (October 29, 2020). "Effect of disease duration in a randomized Phase III trial of rintatolimod, an immune modulator for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome". PLOS ONE. 15 (10): e0240403. doi:10.1371/journal.pone.0240403. ISSN 1932-6203. PMC 7595369. PMID 33119613.
  40. Mariani, Mike (September 3, 2019). "A Town for People with Chronic Fatigue Syndrome". New Yorker. Retrieved April 12, 2022.